RUT 58 60

Drug Profile

RUT 58 60

Alternative Names: RUT58-60

Latest Information Update: 09 Dec 2016

Price : $50

At a glance

  • Originator Oculus Innovative Sciences
  • Developer Pulmatrix
  • Class Antibacterials
  • Mechanism of Action Angiogenesis inducing agents; Cell membrane inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Postoperative infections

Most Recent Events

  • 05 Dec 2016 Oculus innovative Sciences is now called Sonoma Pharmaceuticals
  • 06 Aug 2015 Pulmatrix terminates a phase I/II trial in Post-operative infections in USA (NCT02280395)
  • 09 Jul 2015 Oculus Innovative Sciences receives patent allowance for Microcyn® Technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top